QualityStocks.net News – St. Jude Medical, Inc. (STJ) - Results of Pilot Study Released on Deep Brain Stimulation for Patients with Depression

At www.QualityStocks.Net you can sign up for Quality Stock's Daily Newsletter to find out what Small-Cap and Micro-Cap online Investment Newsletters are interested in, plus hear about the latest news from our clients as well as other publicly traded companies.

We would like to highlight St. Jude Medical, Inc. (STJ). The company develops, manufactures and distributes cardiovascular medical devices for the global cardiac rhythm management, cardiology and cardiac surgery and atrial fibrillation therapy areas and implantable neurostimulation devices for the management of chronic pain. The Company operates in four business segments: Cardiac Rhythm Management (CRM), Cardiovascular (CV), Atrial Fibrillation (AF) and Advanced Neuromodulation Systems (ANS).

In the company’s recent news,

St. Jude, through its ANS Division, announced the results of a pilot study investigating deep brain stimulation (DBS) of Brodmann Area 25 for major depressive disorders. The DBS targeted an area of the brain know as Brodmann Area 25, which appears to become overactive when people are sad and depressed. The results of the study were presented at the American Psychiatric Associations’ meeting in Washington, D.C. by Dr. Sidney Kennedy, psychiatrist-in-chief with the University Health Network in Toronto, Canada.

The study revealed that - after the 6-month procedure - 56 percent of the patients experienced at least a 40 percent decrease in depressive symptoms. Prior to the study, all patients were classified as having severe depression after multiple treatments (including medication, psychotherapy and electroconvulsive therapy) yielded little sustained relief. Based on these results, St. Jude announced the BROADEN™ (BROdmann Area 25 DEep brain Neuromodulation) blind clinical study in February 2008 to further investigate the use of DBS for major depressive disorder, and this study is currently being conducted in the U.S. under an Investigation Device Exemption from the FDA.

About QualityStocks

QualityStocks.net, based in Scottsdale, Arizona is a free service that collects data from hundreds Small-Cap and Micro-Cap online Investment Newsletters into one Free Daily Newsletter Report. QualityStocks.net is dedicated to assisting emerging public companies with their advertising efforts and now has over 500,000+ subscribers that receive The Daily Stock Newsletters.

To sign up for “The QualityStocks Daily Newsletter” please visit www.QualityStocks.net

Please see disclaimer on QualityStocks.net website: http://Disclaimer.QualityStocks.net 

Forward-Looking Statement:

This release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. Risks and uncertainties applicable to the company and its business could cause the company's actual results to differ materially from those indicated in any forward-looking statements.